Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clariant establishes innovation center in Frankfurt
The new, 23,000 square meter innovation center, which will provide space for 500 people, is due to be completed by the end of 2012. The new innovation center
The new, 23,000 square meter innovation center, which will provide space for 500 people, is due to be completed by the end of 2012. The new innovation center
Auspex is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics based on site-specific deuteration of promising drug candidates and clinically validated drugs.
Recently, the South African government has floated a R4.28bn national ARV drugs tender. Sonke Pharmaceuticals, a JV between Ranbaxy (Pty) (70% stake) and Community Investment Holdings (30% stake),
Mankind has already established two manufacturing units at Paonta Sahib in Sirmaur district of Himachal Pradhesh. Mankind Pharma plans to add mosquito repellent, shoe polish and shaving cream
The approval was granted on the basis of a pivotal Phase III trial, in which Tasigna demonstrated superiority to the standard of care Glivec (imatinib) in achieving molecular
Cegedim Relationship Management said that the new office is an important commitment that it is making to the biopharmaceutical industry, supporting companies to expand their commercial activities in
Marina Biotech said the Intellectual Property Office of New Zealand (IPONZ) has issued a notice of acceptance for patent application 563845, titled ‘RNAi Therapeutics for Respiratory Virus Infection.’
Phylogica will employ its proprietary Phylomer drug discovery platform to identify Phylomer peptides suitable for further evaluation. As per the agreement, Phylogica grants Pfizer certain rights, including an
The committee’s positive opinion will now be forwarded to the European Commission for ratification, which typically occurs within two to three months from adoption of the CHMP opinion.
CIT and Biomodels claim the synergy derived from this alliance will enable the two companies to provide their clients with a comprehensive and seamless program of pre-clinical drug